Ovarian Clear Cell Carcinoma Patient Begins LB-100 and Dostarlimab-gxly Combo Therapy

Lixte Biotechnology Holdings, Inc., a pharmaceutical firm listed on the Nasdaq exchange, has initiated a Phase 1b/2 clinical trial to evaluate the potential of their PP2A inhibitor, LB-100, in enhancing the efficacy of GSK's PD-1 blocking antibody, dostarlimab-gxly, for treating ovarian clear cell carcinoma (OCCC). The study is being led by The University of Texas MD Anderson Cancer Center, with LIXTE supplying LB-100 and GSK providing both the monoclonal antibody and financial support for the trial, registered under the identifier NCT06065462.
The rationale for the trial is based on the findings of Amir Jazaeri, MD, a Gynecologic Oncology Professor at MD Anderson, who observed that a genetic decrease in PP2A could increase the sensitivity to immunotherapy. This suggests that LB-100, by pharmacologically reducing PP2A, might amplify the anti-tumor impact of dostarlimab-gxly in OCCC patients without the genetic PP2A reduction.
LIXTE is a clinical-stage company dedicated to identifying novel cancer targets and advancing cancer treatments. Their lead PP2A inhibitor, LB-100, has shown good tolerability in patients and is associated with anti-cancer effects. The company's innovative approach is unique in the market and is protected by an extensive patent portfolio. LIXTE is currently conducting proof-of-concept trials to further validate the potential of LB-100 in improving patient outcomes across various cancer therapies.